- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05220345
Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With CADe (Discovery System) on Adenoma Detection Rate. (DiscoveryIII)
Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With Artificial Intelligence Assisted Polyp Detection (Discovery System) on Adenoma Detection Rate. 'Discovery III Study'
Study Overview
Status
Detailed Description
Rationale: Colonoscopy is the gold standard for CRC screening. The adenoma detection rate (ADR) is the most important quality parameter for colonoscopy, because of its inverse association with the risk of interval CRC. Yet, the adenoma miss rate (AMR) in conventional colonoscopy is reported in meta-analyses to vary between 22-26%. The diagnostic accuracy of colonoscopy highly depends on the quality of inspection of the colonic mucosa during the procedure. To increase the adenoma detection rate (ADR), new polyp/adenoma detection systems based on artificial intelligence (AI) have been developed, i.e., computer assisted detection (CADe). However, these systems still depend on the ability of the endoscopist to adequately visualize the complete colonic mucosa, especially to detect smaller and more subtle lesions. Therefore, we hypothesize that ADR can further be improved by combining a CADe system, the Discovery system, with a behind the fold (BTF) visualization technique, the G-Eye.
Study design: International multicenter prospective interventional cohort, compared with a cohort from the Discovery II study (NL73127.091.20, trial code NL9135). All subjects will be undergoing colonoscopy with a combined BFT and CADe assisted approach. Outcomes will be corrected for confounders using regression modeling.
Study population: 194 Adult patients (>18 years) from 3 hospitals, scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy. Exclusion criteria: inflammatory bowel disease (IBD), known polyp or tumor upon referral, therapeutic procedure (e.g. endoscopic mucosal resection), prior surgical resection of any portion of the colon, American Society of Anesthesiologists score of ≥3, Inadequately corrected anticoagulation disorders or anticoagulation medication use, inability to provide informed consent.
Main study endpoints: The primary objective of the present study is to compare ADR between CADe assisted and a combined BTF/CADe assisted colonoscopy. Secondary objectives include advanced neoplasia rate (including advanced adenomas and/or CRC), polyp detection rate, size and histopathology, mean number of polyps per patient, procedure times, bowel cleaning levels, adverse events, inter-operator variability.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Eligible patients who are scheduled for surveillance colonoscopy will undergo one BFT and CADe assisted colonoscopy. There will be no burden for participants regarding the colonoscopy procedure. Colonoscopy is a commonly performed procedure, and the overall serious adverse event rate is low with an estimated risk 2.8 per 1000 colonoscopies. The risk of experiencing a (serious) adverse event with G-Eye and Discovery guided colonoscopy is believed to be equivalent to conventional colonoscopy. The benefit for patients is a higher likelihood of lesion detection during colonoscopy.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michiel JH Maas, Msc
- Phone Number: +31 629647175
- Email: Michiel.maas@Radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- Recruiting
- Radboud university medical center Nijmegen
-
Contact:
- Michiel HJ Maas, MSc
- Phone Number: +31 629647175
- Email: Michiel.maas@Radboudumc.nl
-
Principal Investigator:
- Peter D. Siersema, prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients (>18 years)
- Referred and scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy.
Exclusion Criteria:
- Inflammatory bowel disease (IBD)
- Known polyp or tumor upon referral
- Therapeutic procedure (e.g., endoscopic mucosal resection)
- Prior surgical resection of any portion of the colon
- American Society of Anesthesiologists score of ≥3
- Inadequately corrected anticoagulation disorder or anticoagulation medication use
- inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: colonoscopy with a combined BFT and CADe assisted approach
This multicenter single-arm colonoscopy trial will compare colonoscopy assisted by both balloon-BFT visualizing and CADe to CADe-only assisted colonoscopy in diagnostic, screening (non-iFOBT based)), or surveillance colonoscopy.
The latter group will be selected from the interventional arm from the Discovery II trial, using corresponding participating centers.
All subjects in this trial will undergo the same treatment, i.e., combined balloon and CADe-assisted colonoscopy.
|
All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system.
Standard of care regarding the colonoscopy procedure will be applied to all study subjects.
Any lesions detected during the procedure will be removed directly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adenoma Detection Rate (ADR)
Time Frame: 30 days after procedure
|
Calculated as the number of patients in whom at least one adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure.
|
30 days after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Advanced adenoma detection rate (AADR).
Time Frame: 30 days after procedure
|
calculated as the number of patients in whom at least one advanced adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
|
30 days after procedure
|
Polyp Detection Rate
Time Frame: 30 days after procedure
|
calculated as the number of patients in whom at least one polyp is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
|
30 days after procedure
|
Sessile detection Rate
Time Frame: 30 days after procedure
|
calculated as the number of patients in whom at least one SSL is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
|
30 days after procedure
|
Indication specific ADR,
Time Frame: 30 days after procedure
|
ADR specific for screening, diagnostic, or surveillance
|
30 days after procedure
|
Mean number of adenomas detected per patient
Time Frame: 30 days after procedure
|
Mean number of adenomas detected per patient
|
30 days after procedure
|
Mean number of polyps detected per patient
Time Frame: 30 days after procedure
|
Mean number of polyps detected per patient
|
30 days after procedure
|
Number of sessile serrated lesions
Time Frame: 30 days after procedure
|
Number of sessile serrated lesions
|
30 days after procedure
|
Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD
Time Frame: 30 days after procedure
|
Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD
|
30 days after procedure
|
Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm
Time Frame: During procedure
|
Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm
|
During procedure
|
Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;
Time Frame: During procedure
|
Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;
|
During procedure
|
Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)
Time Frame: During procedure
|
Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)
|
During procedure
|
Histopathological characteristics of the lesion according to the Vienna classification
Time Frame: 30 days after procedure
|
Histopathological characteristics of the lesion according to the Vienna classification
|
30 days after procedure
|
ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial
Time Frame: At end of study
|
ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial
|
At end of study
|
Bowel cleansing
Time Frame: During procedure
|
Using the Boston Bowel Prep Scale
|
During procedure
|
Cecal intubation rate (CIR)
Time Frame: During procedure
|
Cecal intubation rate (CIR)
|
During procedure
|
Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)
Time Frame: During procedure
|
Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)
|
During procedure
|
Severe) adverse events (S)AEs up to 30 days post-procedure
Time Frame: 30 days after procedure
|
SAEs will be subcategorized into colonoscopy related, cardiac (cardiac ischemia, heart failure, arrhythmia, other) pulmonary (exacerbation COPD, infectious, other), neurological (stroke, cerebrovascular accident, bleeding, other), and other (surgical interventions etc.)
|
30 days after procedure
|
Gloucester Comfort Scale score and analgesia use
Time Frame: During procedure
|
Gloucester Comfort Scale score and analgesia use
|
During procedure
|
Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines
Time Frame: 30 days after procedure
|
Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines
|
30 days after procedure
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Peter D Siersema, Prof, Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL80004.091.21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenoma
-
Fondazione Poliambulanza Istituto OspedalieroCompletedAdenoma Colon | Colonic AdenomaItaly
-
London North West Healthcare NHS TrustCompletedAdenoma Colon | Serrated AdenomaUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingColorectal Adenoma | Colorectal Adenoma With Severe Dysplasia | Colorectal Tubulovillous AdenomaUnited States, Puerto Rico
-
Mansoura UniversityWithdrawn
-
Alexandra Hospital, Athens, GreeceCompletedColonoscopy | Adenoma Detection Rate | Adenoma Miss Rate | RetroflexionGreece
-
Hospital Sirio-LibanesCompletedColorectal Cancer | Colonoscopy | Adenoma Detection Rate | Adenoma Colon | Colorectal Polyp | Sessile Serrated Adenoma | Quality IndicatorBrazil
-
Azienda Unità Sanitaria Locale della RomagnaRecruitingAmpulla of Vater Adenoma | Ampullary Cancer | Ampulla of Vater Cancer | Ampullary AdenomaItaly
-
Stanford UniversityNot yet recruitingHead and Neck Disorder | Warthin Tumor | Pleomorphic Adenoma of the ParotidUnited States
-
Western Sydney Local Health DistrictRecruitingColon Cancer | Colon Adenoma | Adenoma ColonAustralia
-
Peking University Third HospitalRecruitingColorectal AdenomaChina